Literature DB >> 7763002

P-glycoprotein and pharmacokinetics.

D Levêque1, F Jehl.   

Abstract

P-glycoprotein (P-gp) is a transmembrane protein associated with a phenotype of cross resistance to certain anticancer agents. P-gp is thought to act as an energy dependent pump that expels the anticancer drug out of the tumoral cell, reducing its accumulation and hence its activity. P-gp has been detected in vivo and in vitro in numerous tumor cell types but also in normal tissues and particularly in organs involved in the pharmacokinetic behaviour of xenobiotics. The physiologic functions of P-gp remain unclear but a growing amount of information suggests that it can play an important role at the different steps of pharmacokinetics (i.e., absorption, distribution, elimination). This review gives an update on what is known about the impact of P-gp on the disposition of drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7763002

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

1.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study.

Authors:  T H Tsai; S C Liu; P L Tsai; L K Ho; A Y C Shum; C F Chen
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

Review 4.  Carrier-mediated intestinal transport of drugs.

Authors:  A Tsuji; I Tamai
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

5.  Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation.

Authors:  Cedar H A Boakye; Ketan Patel; Apurva R Patel; Henrique A M Faria; Valtencir Zucolotto; Stephen Safe; Mandip Singh
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

6.  Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.

Authors:  J Alsenz; H Steffen; R Alex
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 7.  Drug exsorption from blood into the gastrointestinal tract.

Authors:  K Arimori; M Nakano
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

8.  Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs.

Authors:  A Cavalier; D Levêque; J D Peter; J Salmon; H Elkhaïli; Y Salmon; P Nobelis; J Geisert; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

9.  Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier.

Authors:  P J Gaillard; I C van der Sandt; L H Voorwinden; D Vu; J L Nielsen; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

10.  Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells.

Authors:  E V Batrakova; H Y Han; D W Miller; A V Kabanov
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.